Editas Medicine, Inc.

EDIT

US28106W1036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
5.96 ^USD	+6.24%		+21.38%	-41.16%

Jul. 09	RBC Cuts Price Target on Editas Medicine to $8 From $11, Keeps Sector Perform, Speculative Risk	MT
Jun. 27	Editas Medicine, Inc. Announces Resignation of Akshay Vaishnaw from the Board Effective as of June 30, 2024	CI

Editas Medicine, Inc. Announces Steps Down of Charles Albright as Chief Scientific Officer, Effective January 15

January 11, 2021 at 06:00 am EST

Editas Medicine, Inc. announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity.

Latest news about Editas Medicine, Inc.

RBC Cuts Price Target on Editas Medicine to $8 From $11, Keeps Sector Perform, Speculative Risk	Jul. 09	MT
Editas Medicine, Inc. Announces Resignation of Akshay Vaishnaw from the Board Effective as of June 30, 2024	Jun. 27	CI
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial	Jun. 14	MT
Editas Medicine, Inc. Reports New Safety and Efficacy Data from the Rubber Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association Annual Congress	Jun. 14	CI
Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association Annual Congress	Jun. 14	CI
Evercore ISI Cuts Price Target on Editas Medicine to $7 From $15, Maintains In Line Rating	May. 30	MT
Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing	May. 14	MT
Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating	May. 09	MT
Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight	May. 09	MT
Transcript : Editas Medicine, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	May. 01	MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	May. 01	CI
Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM	Mar. 13
Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating	Feb. 29	MT
Transcript : Editas Medicine, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
Transcript : Editas Medicine, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM	Jan. 09
RBC Boosts Price Target on Editas Medicine to $11 From $8, Keeps Sector Perform Rating	Jan. 03	MT
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update	Dec. 13	DJ
Editas Medicine Enters Licensing Deal With Vertex Pharmaceuticals for Cas9	Dec. 13	MT
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals	Dec. 13	DJ
Editas Medicine and Vertex Pharmaceuticals Enter into Non-Exclusive License Agreement for Cas9	Dec. 13	CI

Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Editas Medicine, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.96 USD

Average target price

14.27 USD

Spread / Average Target

+139.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EDITAS MEDICINE, INC.	-41.16%	490M
MODERNA, INC.	+25.83%	47.96B
LONZA GROUP AG	+44.81%	41.47B
IQVIA HOLDINGS INC.	+0.69%	42.45B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research